A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
The purpose of this study is to determine if epigenetic priming with DNA methyltransferase inhibitors (DMTi) prior to chemotherapy blocks is safe and effective in treating children with acute myeloid leukemia (AML).
The purpose of this study is to compare the good and bad effects of giving either azacitidine OR decitabine before the usual chemotherapy regimen for childhood AML.
- IRB Number: 1905866854
- Research Study Identifier: TX10534
- Principal Investigator: Batra Sandeep, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required